LeMaitre Vascular, Inc. provides devices, implants, and services for the treatment of peripheral vascular disease. The company develops, manufactures, and markets disposable and implantable vascular devices for vascular surgeons, with products used in arteries and veins.
Recurring LMAT news includes quarterly financial results, guidance, dividend declarations, and management presentations at healthcare investor conferences. Company updates also discuss product categories such as Artegraft, grafts, valvulotomes, and carotid shunts, along with sales activity across the Americas, EMEA, and Asia Pacific.
LeMaitre Vascular (Nasdaq:LMAT) has announced that it will release its third quarter 2024 financial results on Thursday, October 31, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook.
Interested parties can access the live call by registering online, after which they will receive dial-in information and a PIN. An audio webcast will also be available live and for replay at www.lemaitre.com/investor.
LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition affecting over 200 million people worldwide. The company focuses on developing, manufacturing, and marketing disposable and implantable vascular devices for vascular surgeons.
LeMaitre Vascular (Nasdaq: LMAT) has announced its participation in three major investor conferences this September. The company's management will be presenting at:
- The Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024, in New York, with President David Roberts presenting at 5:35 PM EST.
- The Barrington Research Fall Investment Conference (Virtual) on September 12, 2024, where Chairman & CEO George W. LeMaitre will host one-on-one meetings.
- The Cantor Fitzgerald 2024 Global Healthcare Conference on September 19, 2024, in New York, with David Roberts presenting at 8:00 AM EST.
These conferences provide LeMaitre Vascular with opportunities to engage with investors and showcase their business strategies and performance.
LeMaitre (Nasdaq:LMAT) reported strong Q2 2024 financial results, with sales reaching $55.8 million, up 11% (12% organic) year-over-year. The company saw significant growth in key product lines and regions, with allografts up 30%, bovine patches up 12%, and carotid shunts up 22%. Geographically, APAC sales increased 20%, EMEA 13%, and the Americas 10%.
Notably, gross margin improved to 68.9%, a 490 basis point increase from Q2 2023, driven by manufacturing efficiencies and higher average selling prices. Operating income surged 52% to $14.4 million, with net income up 46% to $11.8 million. The company announced a quarterly dividend of $0.16 per share and provided an optimistic outlook for Q3 and full-year 2024, projecting continued sales and profit growth.
LeMaitre Vascular (Nasdaq: LMAT) has announced the release date for its second quarter 2024 financial results. The company will disclose its earnings on Thursday, August 1, 2024, after the market closes. Following the release, LeMaitre has scheduled a conference call at 5:00 PM ET to discuss the results, business highlights, and company outlook.
Interested parties can access the live call by registering online, after which they will receive dial-in information and a PIN. Additionally, an audio webcast will be available live and for replay through the company's investor relations website.
LeMaitre Vascular (Nasdaq: LMAT) announced that its Chairman & CEO, George W. LeMaitre, will present at the 2024 Jefferies Global Healthcare Conference on June 6, 2024, at 11:00 AM ET.
The event will take place at the Marriott Marquis in New York City. LeMaitre specializes in devices, implants, and services for peripheral vascular disease, which affects over 200 million people globally.
The company focuses on developing, manufacturing, and marketing disposable and implantable vascular devices for vascular surgeons.
LeMaitre, a provider of vascular devices, implants, and services, reported strong Q1 2024 financial results with sales up 14%, operating income up 51%, and net income up 64%. The company announced a $0.16/share quarterly dividend and provided guidance for Q2 2024 and full-year 2024, expecting double-digit growth in sales, operating income, and EPS. The gross margin improved to 68.6%, driven by increased selling prices and manufacturing efficiencies. The company's CEO expects a 22% operating margin for 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.